Mirta Tad (Mirtazapine)

Mirtazapine, the active ingredient in Mirta Tad, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirta Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant used to address depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depression with insomnia: helps alleviate sleep disturbances associated with depression. - Depression with anxiety: may improve anxiety symptoms that coexist with depressive episodes.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or neutropenia - Severe hypersensitivity reactions - Serotonin syndrome when combined with other serotonergic agents - Suicidal thoughts or worsening depression - Hepatic dysfunction - Seizures (rare)

When prescribing or dispensing Mirta Tad, consider the following precautions. - Hepatic function assessment: evaluate liver status before initiation. - Mood monitoring: watch for worsening depression or emergent suicidal ideation. - Elderly patients: use caution due to increased risk of sedation and falls. - Discontinuation: avoid abrupt cessation to reduce withdrawal phenomena. - Concomitant CNS depressants: monitor for additive sedation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin toxicity. - Alcohol or potent CNS depressants: excessive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihypertensives: additive hypotensive effect. - Carbamazepine: may reduce mirtazapine concentrations, diminishing efficacy.